Product Description
Asenapine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Asenapine is used alone or in combination with other medications to treat or prevent episodes of mania (frenzied, abnormally excited mood) or mixed mania (frenzied, abnormally excited mood and symptoms of depression) in adults and children 10 years of age and older with bipolar I disorder (manic depressive disorder; a disease that causes episodes of mania, episodes of depression and other abnormal moods). Asenapine is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a610015.html)
Mechanisms of Action: 5-HT2A Antagonist,D2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Sublingual
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States
Approved Indications: Schizophrenia | Bipolar Disorder | Schizophrenia
Known Adverse Events: Weight Gain | Bipolar Disorder | Dizziness | Schizophrenia
Company: Organon
Company Location: JERSEY CITY NJ 07302
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20222759 | P3 |
Not yet recruiting |
Schizophrenia |
None |